SWOG clinical trial number
S1937

A Phase III Randomized Trial of Eribulin (NSC #707389) with or without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy.

Open
Phase
III
Accrual
0%
Abbreviated Title
A Phase III Randomized Trial of Eribulin (NSC #707389) with or without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or…
Status Notes
This study is open to accrual effective February 16, 2021.
Activated
02/16/2021
Participants
ALLIANCE, ECOG-ACRIN, NRG, SWOG

Research committees

Genitourinary Cancer

Treatment

Gemcitabine hydrochloride Eribulin mesylate

Reports & Approvals

Trial Locations

Other Clinical Trials

SWOG Clinical Trial Number
CTSU/A031901
SWOG Clinical Trial Number
CTSU/EA8185